M
Muhammad Ramzan
Researcher at French Institute of Health and Medical Research
Publications - 6
Citations - 586
Muhammad Ramzan is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Hepatitis & Hepatocellular carcinoma. The author has an hindex of 5, co-authored 6 publications receiving 560 citations. Previous affiliations of Muhammad Ramzan include Joseph Fourier University & University of Grenoble.
Papers
More filters
Journal ArticleDOI
A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma
Johannes Haybaeck,Nicolas Zeller,Monika Julia Wolf,Achim Weber,Ulrich Wagner,Michael O. Kurrer,Juliane Bremer,Giandomenica Iezzi,Rolf Graf,Pierre-Alain Clavien,Robert Thimme,Hubert E. Blum,Sergei A. Nedospasov,Kurt Zatloukal,Muhammad Ramzan,Sandra Ciesek,Thomas Pietschmann,Patrice N. Marche,Michael Karin,Manfred Kopf,Jeffrey L. Browning,Adriano Aguzzi,Mathias Heikenwalder +22 more
TL;DR: S sustained LT signaling represents a pathway involved in hepatitis-induced HCC, and in vivo LTbetaR stimulation implicates hepatocytes as the major LT-responsive liver cells, and LT betaR inhibition in LTalphabeta-transgenic mice with hepatitis suppresses HCC formation.
Journal ArticleDOI
Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C.
Paula Bonorino,Paula Bonorino,Muhammad Ramzan,Muhammad Ramzan,Xavier Camous,Xavier Camous,Tania Dufeu-Duchesne,Tania Dufeu-Duchesne,M.A. Thelu,M.A. Thelu,Nathalie Sturm,Nathalie Sturm,Aurélie Dariz,Aurélie Dariz,Christiane Guillermet,Christiane Guillermet,Martine Pernollet,Martine Pernollet,Jean-Pierre Zarski,Jean-Pierre Zarski,Patrice N. Marche,Patrice N. Marche,Vincent Leroy,Vincent Leroy,Evelyne Jouvin-Marche,Evelyne Jouvin-Marche +25 more
TL;DR: A significant reduction in NK cell frequency and a quantitative imbalance between CD56(bright) andCD56(dim) subsets were observed in chronic HCV patients as compared to HBV patients, underlining that the inflammatory environment is not the only cause of these phenomena.
Journal ArticleDOI
Characterization and role of intra-hepatic regulatory T cells in chronic hepatitis C pathogenesis
Nathalie Sturm,Nathalie Sturm,M.A. Thelu,M.A. Thelu,Xavier Camous,Xavier Camous,Guéorgui Dimitrov,Guéorgui Dimitrov,Muhammad Ramzan,Muhammad Ramzan,Tania Dufeu-Duchesne,Tania Dufeu-Duchesne,Paula Bonorino,Paula Bonorino,Christiane Guillermet,Elisabeth Brambilla,Elisabeth Brambilla,Philippe Arvers,Martine Pernollet,Martine Pernollet,Vincent Leroy,Vincent Leroy,Jean-Pierre Zarski,Jean-Pierre Zarski,Patrice N. Marche,Patrice N. Marche,Evelyne Jouvin-Marche,Evelyne Jouvin-Marche +27 more
TL;DR: This study provides new insights into the histological localization of Treg within HCV-infected liver, with a special accumulation of CD4(+)FoxP3(+) Treg cells in necro-inflammatory areas, in contact with CD8(+)T cells.
Journal ArticleDOI
Liver-infiltrating CD8+ lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma
Muhammad Ramzan,Muhammad Ramzan,Nathalie Sturm,Nathalie Sturm,Thomas Decaens,Thomas Decaens,Paulette Bioulac-Sage,Brigitte Bancel,Philippe Merle,Jeanne Tran Van Nhieu,Rémy Slama,Rémy Slama,Christian Letoublon,Christian Letoublon,Jean-Pierre Zarski,Jean-Pierre Zarski,Evelyne Jouvin-Marche,Evelyne Jouvin-Marche,Patrice N. Marche,Patrice N. Marche,Vincent Leroy,Vincent Leroy +21 more
TL;DR: The aim of this study was to characterize the immune status of HCV‐related cirrhosis in patients with hepatocellular carcinoma (HCV‐HCC) as compared to HCV patients without hepato Cell carcinoma.
Journal ArticleDOI
IRES complexity before IFN-alpha treatment and evolution of the viral load at the early stage of treatment in peripheral blood mononuclear cells from chronic hepatitis C patients.
M.A. Thelu,Vincent Leroy,Muhammad Ramzan,Tania Dufeu-Duchesne,Patrice N. Marche,Jean-Pierre Zarski +5 more
TL;DR: At the early stage of treatment, IFN alpha‐2a was efficient in reducing the viral replication in a significant number of patients; mechanisms of response might affect the virus directly, however, pre‐treatment genomic variations observed in the 5′NCR of HCV were not a parameter of a later response to antiviral therapy in chronic hepatitis C patients.